18.38
price down icon4.87%   -0.94
pre-market  Pre-market:  18.21   -0.17   -0.92%
loading
Bicara Therapeutics Inc stock is traded at $18.38, with a volume of 361.88K. It is down -4.87% in the last 24 hours and down -16.30% over the past month. Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$19.32
Open:
$19.23
24h Volume:
361.88K
Relative Volume:
1.38
Market Cap:
$1.00B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-16.45%
1M Performance:
-16.30%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$17.62
$20.79
1-Week Range:
Value
$17.62
$24.09
52-Week Range:
Value
$17.62
$28.09

Bicara Therapeutics Inc Stock (BCAX) Company Profile

Name
Name
Bicara Therapeutics Inc
Name
Phone
617-785-8308
Name
Address
245 MAIN STREET, CAMBRIDGE
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
BCAX's Discussions on Twitter

Compare BCAX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
BCAX 18.38 1.00B 0 0 0 0.00
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Bicara Therapeutics Inc Stock (BCAX) Latest News

pulisher
Nov 19, 2024

First Turn Management LLC Takes $14.32 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Bicara Therapeutics (NASDAQ:BCAX) Shares Gap DownWhat's Next? - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

FY2024 EPS Estimates for BCAX Reduced by Cantor Fitzgerald - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

Bicara Therapeutics (NASDAQ:BCAX) Shares Down 6.2%Here's Why - MarketBeat

Nov 15, 2024
pulisher
Nov 13, 2024

Bicara Therapeutics Reports Strong IPO and Clinical Advancements - TipRanks

Nov 13, 2024
pulisher
Nov 12, 2024

Bicara Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Bicara Therapeutics: Newly Minted Upsized IPO With Positive Early Data (NASDAQ:BCAX) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

Bicara's $362M IPO Success Powers Cancer Drug Trial with 64% Response Rate | BCAX Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference - The Manila Times

Nov 11, 2024
pulisher
Nov 09, 2024

Bicara Therapeutics (NASDAQ:BCAX) Rating Increased to Strong-Buy at RODMAN&RENSHAW - Defense World

Nov 09, 2024
pulisher
Nov 06, 2024

Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.33 Consensus Target Price from Analysts - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Bicara Therapeutics stock gets Buy rating from H.C. Wainwright on asset - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Rodman & Renshaw Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat

Nov 05, 2024
pulisher
Oct 23, 2024

Biocon Stole Licensed Cancer Biotech to Fuel Spinoff, Suit Says - Bloomberg Law

Oct 23, 2024
pulisher
Oct 21, 2024

Morgan Stanley spotlights 10 small-cap stocks with at least 50% upside - Kursiv Media

Oct 21, 2024
pulisher
Oct 18, 2024

Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.9%Should You Buy? - MarketBeat

Oct 18, 2024
pulisher
Oct 16, 2024

Balance Sheet Breakdown: Bicara Therapeutics Inc. (BCAX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Oct 16, 2024
pulisher
Oct 11, 2024

In the Green: Bicara Therapeutics Inc. (BCAX) Closes at 19.00, Up/Down -6.40 from Previous Day - The Dwinnex

Oct 11, 2024
pulisher
Oct 10, 2024

Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowWhat's Next? - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

Down rounds don’t aid post-IPO performance - BioCentury

Oct 10, 2024
pulisher
Oct 08, 2024

Bicara shares initiated with Buy on cancer drug potential By Investing.com - Investing.com South Africa

Oct 08, 2024
pulisher
Oct 08, 2024

Bicara stock poised for growth with late-stage transition, Morgan Stanley optimistic - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Bicara Therapeutics stock sees upside with lead drug potential, says Stifel - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Bicara shares initiated with Buy on cancer drug potential - Investing.com India

Oct 08, 2024
pulisher
Oct 08, 2024

Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating By Investing.com - Investing.com South Africa

Oct 08, 2024
pulisher
Oct 08, 2024

Bicara Therapeutics stock sees upside with lead drug potential, says Stifel By Investing.com - Investing.com South Africa

Oct 08, 2024
pulisher
Oct 07, 2024

Three startups aim to raise $400 mln as US biotech IPOs gain traction - Reuters

Oct 07, 2024
pulisher
Oct 04, 2024

Bicara Leads Trio of US Biotech IPOs Raising $703 Million - MSN

Oct 04, 2024
pulisher
Oct 02, 2024

Market Update: Bicara Therapeutics Inc. (BCAX) Sees Negative Movement, Closing at 24.43 - The Dwinnex

Oct 02, 2024
pulisher
Sep 27, 2024

Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors - MSN

Sep 27, 2024
pulisher
Sep 27, 2024

Kiran Mazumdar-Shaw’s niece makes debut at Nasdaq as Bicara Therapeutics goes public - The Financial Express

Sep 27, 2024
pulisher
Sep 26, 2024

With IPO, have the capital and resources for clinical studies: Bicara CEO - The Economic Times

Sep 26, 2024
pulisher
Sep 25, 2024

Bicara Therapeutics Rings the Opening Bell - Nasdaq

Sep 25, 2024
pulisher
Sep 25, 2024

Bicara Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Sep 25, 2024
pulisher
Sep 21, 2024

Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN

Sep 21, 2024
pulisher
Sep 21, 2024

TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc - GuruFocus.com

Sep 21, 2024
pulisher
Sep 19, 2024

James E. Flynn Buys 70,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Upstream Bio goes public amid spate of IPOs - The Pharma Letter

Sep 19, 2024
pulisher
Sep 18, 2024

Ra Capital Management, L.P. Purchases 1,833,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 18, 2024

Ra capital executives buy Bicara Therapeutics shares for $32.99m - Investing.com India

Sep 18, 2024
pulisher
Sep 18, 2024

FMR LLC Acquires New Stake in Bicara Therapeutics Inc - Yahoo Finance

Sep 18, 2024
pulisher
Sep 17, 2024

Deerfield entities buy Bicara Therapeutics shares worth $1.26m By Investing.com - Investing.com Australia

Sep 17, 2024
pulisher
Sep 17, 2024

Deerfield entities buy Bicara Therapeutics shares worth $1.26m - Investing.com

Sep 17, 2024
pulisher
Sep 17, 2024

Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Yahoo Finance

Sep 17, 2024

Bicara Therapeutics Inc Stock (BCAX) Financials Data

There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):